NOS1 and chronic kidney disease: ADMA is an endogenous inhibitor of nitric oxide synthases (NOS), which may in part explain the impaired vasorelaxation, elevated inflammation, and reduced angiogenesis reported in CKD patients and animal models of CKD [17].